Plain-English translation of NCT04935684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether (FMT)—a procedure that transfers healthy gut bacteria from donors into patients—can help prevent a serious complication called graft-versus-host disease after stem cell transplant for blood cancers. After a stem cell transplant, your gut bacteria are often destroyed by the treatment, which can lead to problems with infection and inflammation. The study compares patients who receive this treatment against those who don't, to see if restoring healthy bacteria helps you recover better.
Stem cell transplants save lives but often damage the healthy bacteria in your gut, which can lead to dangerous infections and a painful condition where the new immune cells attack your own body. Researchers believe that giving patients back healthy gut bacteria might prevent these complications and help them survive longer.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the treatment group, you will receive the fecal microbiota transplant after your stem cell transplant as part of your hospital care. If you are assigned to the control group, you will receive standard care without this procedure. All participants will be monitored over one to two years with blood tests, infection checks, and follow-up visits to see how well the treatment works and whether it reduces complications.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
France